Tag: esophageal squamous cell carcinoma

1. Camrelizumab improved the overall survival and the progression-free survival of esophageal squamous cell carcinoma patients compared to placebo treatment as adjuvants to chemotherapy. 2. Grade 3 adverse events were comparably common in the camrelizumab treated group as the placebo group, but there was a greater proportion of pneumonitis, a...
1. Neoadjuvant chemoradiotherapy (NCRT) with surgery improves the death rate, overall survival, disease-free survival time, and locoregional and distal recurrence rates of advanced esophageal squamous cell carcinoma compared to surgery alone 2. While NCRT incurred more adverse events, there was not more treatment-associated deaths, thus the survival benefit could potentially...